1999
Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation
McGuirk J, Seropian S, Howe G, Smith B, Stoddart L, Cooper D. Use of rituximab and irradiated donor-derived lymphocytes to control Epstein–Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplantation 1999, 24: 1253-1258. PMID: 10642818, DOI: 10.1038/sj.bmt.1702052.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntibodies, MonoclonalAntibodies, Monoclonal, Murine-DerivedAntigens, ViralAntineoplastic AgentsBlood Component TransfusionBlood DonorsDNA, ViralGraft vs Host DiseaseHematologic NeoplasmsHematopoietic Stem Cell TransplantationHerpesvirus 4, HumanHumansImmunosuppression TherapyLymphocytesLymphoproliferative DisordersMalePolymerase Chain ReactionRituximabConceptsEpstein-Barr virus-associated lymphoproliferative disorderStem cell transplantationEBV DNA titersB cell populationsCell transplantationTherapeutic strategiesEpstein-Barr virus-associated lymphoproliferationHaplo-identical stem cell transplantationEffective alternative therapeutic strategyAllogeneic stem cell transplantationCourses of rituximabDonor-derived lymphocytesPost-transplant immunosuppressionMonoclonal B-cell populationCD20 monoclonal antibodyCell populationsAlternative therapeutic strategiesImmunosuppressive medicationsSevere GVHDHost diseaseLymphocyte infusionPost transplantFatal complicationCurative therapyLymphoproliferative disorders
1991
Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E. Selective depletion of bone marrow T lymphocytes with anti-CD5 monoclonal antibodies: effective prophylaxis for graft-versus-host disease in patients with hematologic malignancies. Blood 1991, 78: 2139-2149. DOI: 10.1182/blood.v78.8.2139.bloodjournal7882139.Peer-Reviewed Original ResearchAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patientsSelective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies
Antin J, Bierer B, Smith B, Ferrara J, Guinan E, Sieff C, Golan D, Macklis R, Tarbell N, Lynch E, Reichert T, Blythman H, Bouloux C, Rappeport J, Burakoff S, Weinstein H. Selective Depletion of Bone Marrow T Lymphocytes With Anti-CD5 Monoclonal Antibodies: Effective Prophylaxis for Graft-Versus-Host Disease in Patients With Hematologic Malignancies. Blood 1991, 78: 2139-2149. PMID: 1717080, DOI: 10.1182/blood.v78.8.2139.2139.Peer-Reviewed Original ResearchConceptsAnti-CD5 MoAbHigh-risk patientsGraft failureHost diseaseHematologic malignanciesT cellsEpstein-Barr virus-associated lymphoproliferative disorderBone marrowActuarial event-free survivalBone marrow T lymphocytesAnti-CD5 monoclonal antibodyDiagnosis of myelodysplasiaMarrow T lymphocytesEvent-free survivalLow-risk patientsLate graft failureTotal body irradiationSignificant risk factorsRisk of relapseMajor histocompatibility complexActuarial survivalAcute graftAcute GVHDChronic GVHDEvaluable patients